Abstract:Objective: To study the relationship between serum methotrexate concentration and pathophysiological status during high—dose methotrexate treatment for hematological diseases. To provide evidences for population pharmacokinetics study by analyzing the influences of drug elimination, with offering the clinic with adverse reactions statistics. Methods: Data of 1 050 serum methotrexate concentration and the details of cases from Jan.2014 to Feb.2016 were collected. The relationship between serum methotrexate concentration and factors was analyzed, such as age, BWI, dose, infusion lasting time, hepatic and renal function, urine volume, urine pH, serum albumin level, and adverse reactions. Results: Among 1050 cases of Methotrexate serum concentrations, 651(62.00%) within <1.0μmol?L-1, 312(29.71%)within 1~5μmol?L-1, 87(8.29%) whithin ≥ 5.0μmol?L-1. Conclusion: Age, BMI, doses, infusion lasting time, urine volume, Tbil, CrCl, and ALB levels had significant effects on methotrexate serum concentrations, while effects of ALT levels, urine pH showed no statistically significance.
[1] 杨宝峰. 药理学(8 版)[M]. 北京: 人民卫生出版社, 2013, 496~497.
[2] Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neo-plasmas: a report of the BFM group study NHC-BFM 95[J]. Blood, 2005, 105(3):948.
[3] Zhang W, Zhang Q, Zheng T T, et al. Delayed High-dose Methotrexate Excretion and influencing factors in Osteosarcoma Patients[J]. Chin Med J, 2016, 129(21):2530-2534.
[4] Hospira, Inc. Lake Forest I L. Product information:Methotrexate sodium for intramuscular intravenous intra-arterial injection, intramuscular intravenous intra-arterial injection[EB/OL], (2016- 01-11)[2017-3-28]. https://www.accessdata.fda.gov/scripts/cder/daf/ index.cfm?event=overview.process&ApplNo=011719.